Analysis on Availability and Utilization Trends of Four Non-statin Lipid-lowering Drugs from 2020 to 2023 in China
10.3870/j.issn.1004-0781.2025.12.023
- VernacularTitle:2020-2023年4种非他汀类降脂药全国可及性和使用情况分析
- Author:
Jing YANG
1
;
Yong YANG
;
Yuan BIAN
;
Xiaolan LIU
;
Yang LEI
;
Yongjun ZHANG
Author Information
1. 石河子大学药学院,石河子 832003;四川省交通医院药剂科,成都 610097
- Publication Type:Journal Article
- Keywords:
Ezetimibe;
Hybutimibe;
Evolocumab;
Alirocumab;
National drug price negotiation policy;
Centralized drug procurement;
Cholesterol absorption inhibitor;
PCSK9 monoclonal antibodies
- From:
Herald of Medicine
2025;44(12):2039-2044
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the trends in availability and usage for four non-statin lipid-lowering drugs between 2020 and 2023 in China,and to explore the impact of centralized drug procurement and national drug price negotiation policy on the accessibility and utilization trends of these medications.Methods Data processing was performed on four non-statin lipid-lowering drugs(ezetimibe,hybutimibeh,evolocumab,alirocumab)from over 1 000 hospitals within the China Pharmaceutical Association network units from 2020 to 2023 was performed on.SPSS 27.0 was employed for descriptive statistical analysis and x2 tests regarding drug availability,sales revenue,defined daily dose system(DDDs),and cost per DDD(DDDc).Results The availability and DDDs of four cholesterol absorption inhibitors or PCSK9-mAbs increased year by year during the study period,with the most significant increase observed in the first year after centralized drug procurement or national drug price negotiation policy.After the national drug price negotiation policy,alirocumab had the highest availability among the three negotiated drugs.The sales volume of ezetimibe,which was included in the centralized drug procurement program,increased before the negotiation but decreased significantly afterwards,with its share of sales declining year by year.During the study period,the sales volumes and market shares of the three negotiated drugs all increased annually,with evolocumab showing notably higher sales values and percentages than both hybutimibe and alirocumab after the negotiation.The DDDc for all four drugs continued to decrease during the survey period,with the first-year post-centralized drug procurement or national drug price negotiation policy witnessing the largest drop.Conclusion Both of the centralized drug procurement and the national drug price negotiation policy can significantly increase the accessibility to non-statin lipid-lowering drugs and promote their clinical application,however,there is a mismatch between the growth in usage and accessibility for certain varieties.
